Potential of Toll-like receptor 9 agonists in combined anticancer immunotherapy strategies: Synergy of PAMPs and DAMPs?

Immunotherapy

Volumn 3, Issue 3, 2011, Pages 301-304

  Holtick, Udo ^a   Klein Gonzalez, Nela ^a   Von Bergwelt Baildon, Michael S ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

cancer; immunotherapy; TLR9 agonist; vaccine

Indexed keywords

AGATOLIMOD; CPG OLIGODEOXYNUCLEOTIDE; DACARBAZINE; PLATINUM DERIVATIVE; RITUXIMAB; TAXANE DERIVATIVE; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; MODELS, ANIMAL; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOLL-LIKE RECEPTOR 9;

EID: 79952661139     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.118     Document Type: Review

References (25)

1. Luznik L, Fuchs EJ: Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 9(2), 123-137 (2002). (Pubitemid 34457331)
2. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909-915 (2004). (Pubitemid 39273730)
3. O'Neill LA, Bryant CE, Doyle SL: Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol. Rev. 61(2), 177-197 (2009).
4. Bauer S, Kirschning CJ, Hacker H et al.: Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl Acad. Sci. USA 98(16), 9237-9242 (2001). (Pubitemid 32743900)
5. Kim YM, Brinkmann MM, Paquet ME et al.: UNC93B1 delivers nucleotide-sensing Toll-like receptors to endolysosomes. Nature 452(7184), 234-238 (2008). (Pubitemid 351380247)
6. Hacker H: Signal transduction pathways activated by CpG-DNA. Curr. Top. Microbiol. Immunol. 247, 77-92 (2000).
7. Krieg AM, Yi AK, Matson S et al.: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374(6522), 546-549 (1995).
8. Krug A, Rothenfusser S, Hornung V et al.: Identification of CpG oligonucleotide sequences with high induction of IFN-a/b in plasmacytoid dendritic cells. Eur. J. Immunol. 31(7), 2154-2163 (2001). (Pubitemid 32640732)
9. Krieg AM: Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27(2), 161-167 (2008).
10. Weiner GJ, Liu HM, Wooldridge JE et al.: Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl Acad. Sci. USA 94(20), 10833-10837 (1997).
11. Nierkens S, den Brok MH, Roelofsen T et al.: Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PLoS One 4(12), E8368 (2009).
12. Apetoh L, Ghiringhelli F, Tesniere A et al.: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13(9), 1050-1059 (2007). (Pubitemid 47517504)
13. Apetoh L, Tesniere A, Ghiringhelli F et al.: Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 68(11), 4026-4030 (2008).
14. Tesniere A, Schlemmer F, Boige V et al.: Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29(4), 482-491 (2009).
15. Martins I, Kepp O, Galluzzi L et al.: Surface-exposed calreticulin in the interaction between dying cells and phagocytes. Ann. NY Acad. Sci. 1209, 77-82 (2010).
16. Obeid M, Tesniere A, Ghiringhelli F et al.: Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13(1), 54-61 (2007). (Pubitemid 46067386)
17. Peng RQ, Chen YB, Ding Y et al.: Expression of calreticulin is associated with infiltration of T-cells in stage IIIb colon cancer. World J. Gastroenterol. 16(19), 2428-2434 (2010).
18. Huang B, Zhao J, Unkeless JC et al.: TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27(2), 218-224 (2008).
19. Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C et al.: Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood 112(6), 2205-2213 (2008).
20. Bertin S, Samson M, Pons C et al.: Comparative proteomics study reveals that bacterial CpG motifs induce tumor cell autophagy in vitro and in vivo. Mol. Cell. Proteomics 7(12), 2311-2322 (2008).
21. Chaturvedi A, Dorward D, Pierce SK: The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity 28(6), 799-809 (2008).
22. Manegold C, Gravenor D, Woytowitz D et al.: Randomized Phase II trial of a Toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26(24), 3979-3986 (2008).
23. Weber JS, Zarour H, Redman B et al.: Randomized Phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer 115(17), 3944-3954 (2009).
24. Brody JD, Ai WZ, Czerwinski DK et al.: In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a Phase I/II study. J. Clin. Oncol. 28(28), 4324-4332 (2010).
25. Leonard JP, Link BK, Emmanouilides C et al.: Phase I trial of Toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin. Cancer Res. 13(20), 6168-6174 (2007). (Pubitemid 350075077)